Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CELL GENESYS INC (CEGE)
|
Add to portfolio |
|
|
|
| Price: |
$0.27
| | Metrics |
| OS: |
92.2
|
M
| |
-105
|
% ROE
|
| Market cap: |
$25.1
|
M
| |
140
|
% ROIC
|
|
Net cash:
|
$32.9
|
M
| |
$0.36
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$16.4
|
M
| |
-0.5
|
x EV/EBITDA
|
|
EBIT
|
$8.6
|
M
| |
-0.9
|
x EV/EBIT
|
| EPS |
($0.40)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 |
| Revenues | 94.6 | 1.4 | 1.4 | 4.6 | 11.5 | 18.1 | 39.1 | 28.3 |
| Revenue growth | 6753.0% | 1.2% | -70.2% | -60.0% | -36.8% | -53.7% | 38.2% | |
| Cost of goods sold | 103.1 | 20.4 | 18.0 | 18.7 | 17.9 | 26.0 | 20.7 | 11.9 |
| Gross profit | -8.5 | -19.0 | -16.7 | -14.1 | -6.5 | -7.9 | 18.4 | 16.5 |
| Gross margin | -9.0% | -1378.3% | -1222.7% | -307.8% | -56.5% | -43.3% | 47.1% | 58.2% |
| General and administrative | 17.5 | 20.4 | 17.9 | 16.3 | 17.9 | 26.0 | 20.7 | 11.9 |
| EBIT | -15.5 | -125.2 | -112.9 | -104.2 | -98.6 | -93.1 | -56.5 | -52.3 |
| EBIT margin | -16.3% | -9069.0% | -8278.0% | -2272.3% | -860.6% | -513.8% | -144.4% | -184.8% |
| Pre-tax income | -53.2 | -125.2 | -53.3 | -59.0 | -93.7 | -81.0 | -45.2 | -34.2 |
| Income taxes | -6.2 | -25.9 | 29.6 | 5.9 | 3.7 | -24.6 | -18.6 | -5.5 |
| Tax rate | 11.7% | 20.7% | | | | 30.4% | 41.2% | 16.1% |
| Net income | -47.0 | -99.3 | -82.9 | -64.9 | -97.4 | -56.4 | -26.6 | -28.7 |
| Net margin | -49.7% | -7193.8% | -6079.8% | -1416.6% | -850.2% | -311.2% | -68.0% | -101.3% |
| |
| Diluted EPS | ($0.56) | ($1.39) | ($1.67) | ($1.43) | ($2.23) | ($1.48) | ($0.74) | ($0.83) |
| Shares outstanding (diluted) | 83.6 | 71.3 | 49.7 | 45.4 | 43.7 | 38.2 | 35.9 | 34.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|